Glaxo Wellcome Flovent
Executive Summary
Pharmacodynamic and pharmacokinetic comparisons of fluticasone and other inhaled corticosteroids in a Flovent detail aid represent "unsubstantiated implied superiority claims," FDA tells company in April 8 notice of violation letter. The detail aid claim that Flovent's oral bioavailablity is the lowest in the class lacks fair balance, FDA adds. Although the oral bioavailability is negligible (<1%), FDA points out that the majority of fluticasone delivered to the lung is systemically absorbed, making the systemic bioavailability about 30% of the dose delivered
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth